Oryzon Genomics S.A. (ORYZF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oryzon Genomics S.A. (ORYZF) trades at $3.65 with AI Score 49/100 (Grade C). Oryzon Genomics S. A. is a clinical-stage biopharmaceutical company focused on epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. Market cap: $282.54M, Sector: Healthcare.
Last analyzed: Mar 15, 2026Analyst Coverage for ORYZF: ORYZF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ORYZF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ORYZF: 2/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
Oryzon Genomics S.A. (ORYZF) Healthcare & Pipeline Overview
Oryzon Genomics S.A., a Spanish biopharmaceutical company, specializes in developing epigenetic therapies for oncology and CNS diseases. Their pipeline features LSD1 inhibitors like iadademstat and vafidemstat, currently in Phase II trials, positioning them in the competitive biotechnology landscape with a focus on innovative treatments.
What Is the Investment Thesis for ORYZF?
Oryzon Genomics presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biopharmaceutical companies. The primary value driver is the successful development and commercialization of iadademstat and vafidemstat. Positive Phase II trial results could serve as a major catalyst, potentially leading to partnerships or acquisition. However, the company's reliance on a limited number of drug candidates and the inherent risks associated with clinical trials represent significant potential downsides. With a market cap of $0.26 billion and negative P/E ratio of -83.93, the company's valuation is heavily dependent on future clinical and regulatory milestones. The low beta of 0.36 suggests lower volatility compared to the overall market, but this does not mitigate the substantial risks specific to the biotechnology industry.
Based on FMP financials and quantitative analysis
ORYZF Key Highlights
- Oryzon Genomics is a clinical-stage biopharmaceutical company focused on epigenetics-based therapeutics.
- Lead compounds iadademstat (ORY-1001) and vafidemstat (ORY-2001) are in Phase II clinical trials for oncology and CNS disorders, respectively.
- The company's pipeline includes ORY-3001, an LSD1 inhibitor in preclinical development for non-oncological diseases.
- Oryzon Genomics has a market capitalization of $0.26 billion.
- The company's P/E ratio is -83.93, reflecting its current lack of profitability and reliance on future clinical and commercial success.
Who Are ORYZF's Competitors?
ORYZF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GNFTF Genfit S.A. | $9.98 | -2.16% | $499.80M | 73 |
| HNSBF Hansa Biopharma AB (publ) | $2.90 | +0.00% | $245.80M | 63 |
| JWCTF JW (Cayman) Therapeutics Co. Ltd | $0.24 | +0.00% | $98.91M | 54 |
| NGENF NervGen Pharma Corp. | $3.95 | -2.47% | $312.89M | — |
| SNDX Syndax Pharmaceuticals, Inc. | $18.02 | +0.61% | $1.60B | 79 |
| ANAB AnaptysBio, Inc. | $54.24 | +4.11% | $2.34B | 79 |
| ABCL AbCellera Biologics Inc. | $5.23 | -0.76% | $1.60B | 76 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ORYZF's Key Strengths?
- Proprietary epigenetic drug development platform.
- Clinical-stage pipeline with promising drug candidates.
- Expertise in LSD1 inhibition.
- Strong intellectual property position.
What Are ORYZF's Weaknesses?
- Limited financial resources.
- Reliance on a small number of drug candidates.
- High risk of clinical trial failure.
- Lack of commercial infrastructure.
What Could Drive ORYZF Stock Higher?
- Publication of Phase II clinical trial results for iadademstat in oncology.
- Publication of Phase II clinical trial results for vafidemstat in CNS disorders.
- Initiation of clinical trials for ORY-3001 in non-oncological diseases.
- Advancement of iadademstat and vafidemstat through clinical development.
- Potential for strategic partnerships with larger pharmaceutical companies.
What Are the Key Risks for ORYZF?
- Clinical trial failures for iadademstat or vafidemstat.
- Regulatory hurdles in obtaining marketing approvals.
- Competition from other biotechnology companies.
- Limited financial resources.
- Dependence on a small number of drug candidates.
What Are the Growth Opportunities for ORYZF?
- Iadademstat (ORY-1001) in Oncology: Iadademstat, a selective LSD1 inhibitor, is currently in Phase II clinical trials for various oncology indications. The oncology market is substantial, with a global market size projected to reach $536.53 billion by 2030. Positive Phase II results could lead to partnerships with larger pharmaceutical companies for Phase III trials and eventual commercialization. Success in specific cancer subtypes with high unmet needs could provide a significant competitive advantage. Timeline: Potential Phase III trials could commence within the next 2-3 years, pending Phase II outcomes.
- Vafidemstat (ORY-2001) in CNS Disorders: Vafidemstat, a CNS-optimized LSD1 inhibitor, is in Phase II trials for CNS and psychiatric diseases, including schizophrenia and Alzheimer's disease. The CNS therapeutics market is also large, estimated at $147 billion in 2023. Successful clinical trials could open up opportunities in treating these debilitating conditions. The drug's CNS optimization could differentiate it from other LSD1 inhibitors. Timeline: Similar to iadademstat, Phase III trials could begin in 2-3 years, contingent on Phase II results.
- Expansion of Epigenetic Pipeline: Oryzon's focus on epigenetics provides opportunities to expand its pipeline with new drug candidates targeting different epigenetic mechanisms. The epigenetics market is growing as researchers discover new therapeutic targets. Investing in early-stage research and development could lead to the discovery of novel treatments for various diseases. Timeline: New drug candidates could enter preclinical development within the next 1-2 years.
- Strategic Partnerships and Licensing Agreements: Oryzon can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Licensing agreements could provide upfront payments, milestone payments, and royalties on future sales. These partnerships can provide financial resources and expertise to navigate the complex regulatory landscape and commercialize its products. Timeline: Partnership agreements could be established within the next year.
- ORY-3001 for Non-Oncological Diseases: ORY-3001, currently in preclinical development, targets non-oncological diseases. This represents a diversification of Oryzon's pipeline and potential entry into new therapeutic areas. Success in preclinical studies could lead to clinical trials and eventual commercialization. The market for non-oncological diseases is vast, offering significant opportunities for Oryzon. Timeline: Clinical trials for ORY-3001 could commence within the next 2-3 years, pending preclinical results.
What Opportunities Does ORYZF Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion of epigenetic pipeline.
- Positive clinical trial results.
- Growing market for targeted therapies.
What Threats Does ORYZF Face?
- Competition from other biotechnology companies.
- Regulatory hurdles.
- Clinical trial failures.
- Patent expirations.
What Are ORYZF's Competitive Advantages?
- Proprietary epigenetic drug development platform.
- Strong intellectual property protection for its drug candidates.
- Clinical data supporting the efficacy and safety of its drugs.
- Expertise in LSD1 inhibition.
What Does ORYZF Do?
Oryzon Genomics S.A., founded in 2000 and headquartered in Cornellà de Llobregat, Spain, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative epigenetic-based therapeutics. The company focuses on addressing unmet medical needs in oncology and central nervous system (CNS) disorders. Oryzon's core expertise lies in modulating epigenetic targets, particularly lysine-specific demethylase 1 (LSD1), to develop novel treatments. Their lead compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor currently in Phase II clinical trials for various oncology indications. Another key asset is vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor also in Phase II trials, targeting CNS and psychiatric diseases such as schizophrenia and Alzheimer's disease. Additionally, Oryzon has ORY-3001, an LSD1 inhibitor in preclinical development for non-oncological diseases. Oryzon operates primarily in Europe, focusing on research, clinical development, and potential commercialization of its drug candidates. The company aims to establish strategic partnerships to expand its reach and accelerate the development and commercialization of its innovative therapies. Oryzon's commitment to epigenetics and its focus on challenging diseases position it as a player in the biotechnology sector, striving to improve patient outcomes through novel therapeutic approaches.
What Products and Services Does ORYZF Offer?
- Develop epigenetics-based therapeutics.
- Focus on treatments for cancer and CNS disorders.
- Develop LSD1 inhibitors.
- Conduct Phase II clinical trials for iadademstat (ORY-1001) in oncology.
- Conduct Phase II clinical trials for vafidemstat (ORY-2001) in CNS and psychiatric diseases.
- Engage in preclinical development of ORY-3001 for non-oncological diseases.
How Does ORYZF Make Money?
- Develop and out-license or sell novel epigenetic drugs.
- Conduct clinical trials to demonstrate drug efficacy and safety.
- Seek regulatory approvals from authorities like the EMA and FDA.
- Potentially commercialize drugs directly or through partnerships.
What Industry Does ORYZF Operate In?
Oryzon Genomics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The epigenetics market, where Oryzon specializes, is gaining traction as researchers uncover the role of epigenetic modifications in various diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms focusing on similar therapeutic areas. Success in this industry requires substantial investment in research and development, navigating complex clinical trials, and securing regulatory approvals. Market trends indicate a growing demand for targeted therapies and personalized medicine, aligning with Oryzon's focus on epigenetic-based treatments.
Who Are ORYZF's Key Customers?
- Patients with cancer.
- Patients with CNS disorders.
- Pharmaceutical companies (potential partners or acquirers).
- Healthcare providers.
ORYZF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Oryzon's future, as executives are investing their own money.
- Community sentiment has shifted positively, with discussions around the potential of their epigenetic therapies gaining traction.
- New collaborations announced in the last month indicate a growing interest from larger pharmaceutical companies, enhancing credibility.
- The ongoing clinical trials show promising preliminary results, fueling optimism among investors and stakeholders.
Bear Case
- Concerns about the competitive landscape are rising, with several biotech firms advancing similar therapies, which may dilute Oryzon's market share.
- Social sentiment reflects skepticism regarding the timeline for product commercialization, with some investors doubting the speed of progress.
- Recent regulatory challenges in the biotech sector have created an air of uncertainty, making investors cautious about Oryzon's prospects.
- Market perception is mixed, as some analysts highlight the risks associated with biotech investments, particularly in early-stage companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ORYZF Latest News
No recent news available for ORYZF.
ORYZF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ORYZF.
Price Targets
Wall Street price target analysis for ORYZF.
ORYZF MoonshotScore
What does this score mean?
The MoonshotScore rates ORYZF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Carlos Manuel Buesa Arjol
CEO
Carlos Manuel Buesa Arjol serves as the CEO of Oryzon Genomics S.A. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held various leadership positions, contributing to strategic decision-making and business development. His expertise spans areas such as drug development, clinical trials, and commercialization strategies. He is responsible for managing the company's overall operations and driving its growth initiatives. He is responsible for managing 47 employees.
Track Record: Under Carlos Manuel Buesa Arjol's leadership, Oryzon Genomics has advanced its lead compounds, iadademstat and vafidemstat, into Phase II clinical trials. He has overseen the company's strategic focus on epigenetics-based therapeutics and the expansion of its pipeline. His leadership has been instrumental in securing funding and partnerships to support the company's research and development efforts. He has successfully guided the company through various milestones in its clinical programs.
ORYZF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Oryzon Genomics S.A. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading volume can be thin. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to less stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited information disclosure due to less stringent reporting requirements.
- Lower liquidity and wider bid-ask spreads.
- Potential for price manipulation due to lower trading volume.
- Higher risk of fraud or scams compared to listed exchanges.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with the OTC market.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Confirm the company's contact information and physical address.
- The company has a website and actively communicates with investors.
- The company has a clear business plan and strategy.
- The company has a management team with relevant experience.
- The company is developing innovative epigenetic-based therapeutics.
- The company's lead compounds are in Phase II clinical trials.
ORYZF Healthcare Stock FAQ
What does Oryzon Genomics S.A. do?
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. Their lead compounds, iadademstat (ORY-1001) and vafidemstat (ORY-2001), are in Phase II clinical trials targeting various oncology indications and CNS/psychiatric diseases, respectively. The company leverages its expertise in epigenetic modulation, particularly LSD1 inhibition, to create novel treatments for unmet medical needs. They also have a pre-clinical asset, ORY-3001, for non-oncological diseases, demonstrating commitment to expanding their therapeutic reach.
What do analysts say about ORYZF stock?
As of March 15, 2026, there is no readily available analyst consensus on ORYZF due to its OTC listing and clinical-stage nature. Valuation is primarily driven by the potential success of its clinical pipeline, particularly iadademstat and vafidemstat. Investors should closely monitor clinical trial results and regulatory milestones as key indicators of future growth. The company's negative P/E ratio reflects its current lack of profitability, emphasizing the speculative nature of the investment.
What are the main risks for ORYZF?
The primary risks for Oryzon Genomics S.A. include the inherent uncertainties of clinical drug development, particularly the possibility of clinical trial failures for iadademstat and vafidemstat. Regulatory hurdles in obtaining marketing approvals also pose a significant risk. Competition from other biotechnology companies developing similar therapies could impact market share. Furthermore, the company's limited financial resources and reliance on a small number of drug candidates increase its vulnerability to adverse events.
What are the key factors to evaluate for ORYZF?
Oryzon Genomics S.A. (ORYZF) holds an AI score of 49/100 (low). Not financial advice.
How frequently does ORYZF data refresh on this page?
ORYZF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ORYZF's recent stock price performance?
Oryzon Genomics S.A. (ORYZF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary epigenetic drug development platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ORYZF overvalued or undervalued right now?
Valuing Oryzon Genomics S.A. (ORYZF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ORYZF?
Before investing in Oryzon Genomics S.A. (ORYZF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.
- AI analysis pending for ORYZF.